The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Immunomedics; Novartis
 
Jennifer Robinson Diamond
Research Funding - Casi Pharmaceuticals
 
Wells A. Messersmith
Consulting or Advisory Role - Immunomedics; OncoMed
Research Funding - GlaxoSmithKline; Immunomedics; Millennium; OncoMed; Pfizer; Roche/Genentech
 
Ingrid A. Mayer
Consulting or Advisory Role - Genentech/Roche; Novartis
Research Funding - Novartis
 
Steven J. Isakoff
Consulting or Advisory Role - BIND Biosciences; Myriad Genetics
Research Funding - Abbvie; Genentech; PharmaMar
Travel, Accommodations, Expenses - Genentech; Myriad Genetics
 
Vandana Gupta Abramson
Consulting or Advisory Role - Novartis
Research Funding - Astellas Pharma; Genentech/Roche
 
Jordan Berlin
Consulting or Advisory Role - Boston Biomedical; Celgene; EMD Serono; Genentech/Roche; Ipsen; Janssen Oncology; Lilly/ImClone; Novartis; Pharmacyclics; Symphony Evolution; Targovax; Threshold Pharmaceuticals; Vertex
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Abbvie; Boston Biomedical; Celgene; Genentech/Roche; Janssen Oncology
Other Relationship - Momenta Pharmaceuticals; Symphony Evolution
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
Joyce O'Shaughnessy
Research Funding - Immunomedics (Inst)
 
Kevin Kalinsky
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Honoraria - Amgen; AstraZeneca; Immunomedics; pfizer
 
Rebecca L. Moroose
Research Funding - Immunomedics (Inst)
 
Nikita C. Shah
Research Funding - Immunomedics (Inst)
 
Dejan Juric
Consulting or Advisory Role - BIND Therapeutics; Blend Therapeutics; Eisai; EMD Serono; Novartis
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; EMD Serono; G1 Therapeutics; Lilly; Takeda; Tesaro; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Michael J. Guarino
Research Funding - Immunomedics (Inst)
 
Allyson J. Ocean
Research Funding - Immunomedics (Inst)
 
Francois Wilhelm
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Robert M. Sharkey
Employment - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
David M. Goldenberg
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Patents, Royalties, Other Intellectual Property - Patent protection for multiple antibody-based products and procedures
 
Linda T. Vahdat
Research Funding - Immunomedics (Inst)